Overview * ProKidney ended Q3 2025 with $272 mln in cash, supporting operations into mid-2027 Outlook * Company expects cash to support operations into mid-2027 Result Drivers * R&D EXPENSES - Decrease in R&D expenses due to winding down of completed or terminated trials Key Details Metric Beat/Mis Actual Consensu s s Estimate Q3 $38.76 Operatin mln g Expenses Q3...

Overview * Theravance Q3 revenue slightly beats estimates, driven by Viatris collaboration * Adjusted net income for Q3 beats estimates, reflecting financial discipline * YUPELRI net sales in Q3 reach $71.4 mln, up 15% YoY Outlook * Theravance expects topline Phase 3 CYPRESS results in Q1 2026 * Company on track to achieve $50 mln TRELEGY sales milestone in 2025...

Overview * TechTarget ( TTGT ) Q3 revenue slightly beats analyst expectations, growing 1% year-on-year * Company reports Q3 net loss of $76.8 mln, impacted by non-cash impairment * Adjusted EBITDA for Q3 grows 9% year-on-year, reflecting operational progress Outlook * Company reaffirms 2025 full-year guidance for flat revenues and Adjusted EBITDA of $85 mln * Company expects operating momentum...

04:33 PM EST, 11/10/2025 (MT Newswires) -- TeraWulf ( WULF ) reported a Q3 loss late Monday of $1.13 per diluted share, widening from a loss of $0.06 a year earlier. Analysts surveyed by FactSet expected a loss of $0.04. Revenue for the three months ended Sept. 30 was $50.6 million, up from $27.1 million a year earlier. Analysts polled...